TITLE

Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell line

AUTHOR(S)
ZHENG-XIAO OUYANG; XIAN-AN LI
PUB. DATE
August 2013
SOURCE
Oncology Letters;2013, Vol. 6 Issue 4, p970
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The present study aimed to compare the combined effect of tamoxifen (TAM) and doxorubicin (ADM) with the individual effects of TAM and ADM alone on the MG63 human osteosarcoma cell line. Estrogen receptor (ER) expression was detected in the MG63 cells using reverse transcription PCR. The morphological changes during the inhibition of cell growth were observed using an inverted microscope and a 3-(4, 5-dimethy1-2-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) colorimetric assay following the individual or combined addition of TAM and ADM. ERa and ERp expression was detected in the MG63 cells. The typical apoptotic cell morphology was observed in all groups, with the exception of the control group. The MTT colorimetric analysis demonstrated that the rate of inhibition of cell proliferation in the combination group was significantly increased compared with that in the other groups (P<0.05). ERa and ERp expression was detected in the MG63 human osteosarcoma cells. TAM and ADM alone were able to inhibit cell proliferation. The combination of TAM and ADM significantly enhanced the inhibitory effect, partly through the enhanced sensitivity of the cells to ADM by TAM, which caused the inhibition of cell proliferation and apoptosis.
ACCESSION #
110397634

 

Related Articles

  • Tamoxifen and its New Derivatives in Cancer Research. Rivera-Guevara, Claudia; Camacho, Javier // Recent Patents on Anti-Cancer Drug Discovery;May2011, Vol. 6 Issue 2, p237 

    A major challenge in cancer research is to discover drugs with high selectivity and minor side-effects. Tamoxifen has been widely used for more than 30 years in breast cancer treatment and prevention. Tamoxifen acts mainly via estrogen receptors (ER), but also displays anti-tumor activity in...

  • Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER a and ß subtypes via an Sp1 site. Salvatori, Luisa; Pallante, Pierlorenzo; Ravenna, Linda; Chinzari, Patrizia; Frati, Luigi; Russo, Matteo A; Petrangeli, Elisa // Oncogene;7/31/2003, Vol. 22 Issue 31, p4875 

    Through the analysis of the transient expression of the luciferase reporter gene in HeLa cells, an evaluation has been made of the transcriptional activity of oestrogens and of selective oestrogen receptor (ER) modulators (SERMs), mediated by the a and ß isoforms of the ER, on the epidermal...

  • Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. Loi, Sherene; Haibe-Kains, Benjamin; Desmedt, Christine; Wirapati, Pratyaksha; Lallemand, Françoise; Tutt, Andrew M.; Gillet, Cheryl; Ellis, Paul; Ryder, Kenneth; Reid, James F.; Daidone, Maria G.; Pierotti, Marco A.; Berns, Els M. J. J.; Jansen, Maurice P. H. M.; Foekens, John A.; Delorenzi, Mauro; Bontempi, Gianluca; Piccart, Martine J.; Sotiriou, Christos // BMC Genomics;2008, Vol. 9, Special section p1 

    Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen...

  • Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Cittelly, Diana M.; Das, Partha M.; Salvo, Virgilio A.; Fonseca, Juan P.; Burow, Matthew E.; Jones, Frank E. // Carcinogenesis;Dec2010, Vol. 31 Issue 12, p2049 

    Tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (ER)α-positive breast tumors. Tumor resistance to tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress human epidermal growth factor receptor 2 (HER2)....

  • Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer. Kok, Marleen; Holm-Wigerup, Caroline; Hauptmann, Michael; Michalides, Rob; Stål, Olle; Linn, Sabine; Landberg, Göran // JNCI: Journal of the National Cancer Institute;12/16/2009, Vol. 101 Issue 24, p1725 

    Although estrogen receptor-α (ERα) is a marker used to identify breast cancer patients most likely to benefit from endocrine therapy, approximately 50% of ERα-positive breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that phosphorylation of ERα at...

  • Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study. Lyng, Maria B.; Lænkholm, Anne-Vibeke; Søkilde, Rolf; Gravgaard, Karina H.; Litman, Thomas; Ditzel, Henrik J. // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Purpose: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer...

  • Individualized identification of disease-associated pathways with disrupted coordination of gene expression. Hongwei Wang; Hao Cai; Lu Ao; Haidan Yan; Wenyuan Zhao; Lishuang Qi; Yunyan Gu; Zheng Guo // Briefings in Bioinformatics;Jan2016, Vol. 17 Issue 1, p78 

    Current pathway analysis approaches are primarily dedicated to capturing deregulated pathways at the population level and cannot provide patient-specific pathway deregulation information. In this article, the authors present a simple approach, called individPath, to detect pathways with...

  • An Integrated Bioinformatics Approach Identifies Elevated Cyclin E2 Expression and E2F Activity as Distinct Features of Tamoxifen Resistant Breast Tumors. Huang, Lei; Zhao, Shuangping; Frasor, Jonna M.; Dai, Yang // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Approximately half of estrogen receptor (ER) positive breast tumors will fail to respond to endocrine therapy. Here we used an integrative bioinformatics approach to analyze three gene expression profiling data sets from breast tumors in an attempt to uncover underlying mechanisms contributing...

  • A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen. Lebedeva, Galina; Yamaguchi, Azusa; Langdon, Simon P.; Macleod, Kenneth; Harrison, David J. // BMC Systems Biology;2012, Vol. 6 Issue 1, p1 

    Background: Estrogen receptors alpha (ER) are implicated in many types of female cancers, and are the common target for anti-cancer therapy using selective estrogen receptor modulators (SERMs, such as tamoxifen). However, cell-type specific and patient-to-patient variability in response to SERMs...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics